Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors.

Naour AL, Prat M, Thibault B, Mével R, Lemaitre L, Leray H, Joubert MV, Coulson K, Golzio M, Lefevre L, Mery E, Martinez A, Ferron G, Delord JP, Coste A, Couderc B.

J Mol Cell Biol. 2019 Sep 3. pii: mjz090. doi: 10.1093/jmcb/mjz090. [Epub ahead of print]

PMID:
31504643
2.

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.

Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, López-Picazo JM, Machiels JP, Delord JP, Evans TRJ, Boni V, Calvo E, Topalian SL, Chen T, Soumaoro I, Li B, Gu J, Zwirtes R, Moore KN.

J Clin Oncol. 2019 Sep 5:JCO1900739. doi: 10.1200/JCO.19.00739. [Epub ahead of print]

PMID:
31487218
3.

Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study.

Garrel R, Mazel M, Perriard F, Vinches M, Cayrefourcq L, Guigay J, Digue L, Aubry K, Alfonsi M, Delord JP, Lallemant B, Even C, Daurès JP, Landais P, Cupissol D, Alix-Panabières C.

Clin Chem. 2019 Oct;65(10):1267-1275. doi: 10.1373/clinchem.2019.305904. Epub 2019 Aug 6.

PMID:
31387885
4.

Phase I Study of Emactuzumab Single Agent or in Combination with Paclitaxel in Patients with Advanced/Metastatic Solid Tumors Reveals Depletion of Immunosuppressive M2-like Macrophages.

Gomez-Roca CA, Italiano A, Le Tourneau C, Cassier PA, Toulmonde M, D'Angelo SP, Campone M, Weber KL, Loirat D, Cannarile MA, Jegg AM, Ries C, Christen R, Meneses-Lorente G, Jacob W, Klaman I, Ooi CH, Watson C, Wonde K, Reis B, Michielin F, Rüttinger D, Delord JP, Blay JY.

Ann Oncol. 2019 May 22. pii: mdz163. doi: 10.1093/annonc/mdz163. [Epub ahead of print]

PMID:
31114846
5.

The GIRAFE phase II trial on MVCT-based "volumes of the day" and "dose of the day" addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer.

Esteyrie V, Gleyzolle B, Lusque A, Graff P, Modesto A, Rives M, Lapeyre M, Desrousseaux J, Graulières E, Hangard G, Arnaud FX, Ferrand R, Delord JP, Poublanc M, Mounier M, Filleron T, Laprie A.

Clin Transl Radiat Oncol. 2019 Mar 9;16:34-39. doi: 10.1016/j.ctro.2019.02.006. eCollection 2019 May.

6.

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.

Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A.

J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3.

PMID:
30943124
7.

Definitive radiochemotherapy or initial surgery for oropharyngeal cancer : To what extent can p16 expression be used in the decision process?

Modesto A, Galissier T, Lusque A, Delord JP, Uro-Coste E, Sarini J, Mouchet F, Lopez R, Laprie A, Graff P, Vergez S, Rives M.

Strahlenther Onkol. 2019 Jun;195(6):496-503. doi: 10.1007/s00066-019-01451-8. Epub 2019 Mar 15.

PMID:
30877351
8.

Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.

Le Louedec F, Alix-Panabières C, Lafont T, Allal BC, Garrel R, Digue L, Guigay J, Cupissol D, Delord JP, Lallemant B, Alfonsi M, Aubry K, Mazel M, Becher F, Perriard F, Chatelut E, Thomas F.

Br J Clin Pharmacol. 2019 Jun;85(6):1357-1366. doi: 10.1111/bcp.13907. Epub 2019 Apr 13.

PMID:
30811063
9.

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.

Laprie A, Ken S, Filleron T, Lubrano V, Vieillevigne L, Tensaouti F, Catalaa I, Boetto S, Khalifa J, Attal J, Peyraga G, Gomez-Roca C, Uro-Coste E, Noel G, Truc G, Sunyach MP, Magné N, Charissoux M, Supiot S, Bernier V, Mounier M, Poublanc M, Fabre A, Delord JP, Cohen-Jonathan Moyal E.

BMC Cancer. 2019 Feb 21;19(1):167. doi: 10.1186/s12885-019-5317-x.

10.

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, Delord JP, Dowlati A, Kochuparambil ST, Taylor MH, Powderly JD, Vaishampayan UN, Verschraegen C, Grote HJ, von Heydebreck A, Chin K, Gulley JL.

JAMA Oncol. 2019 Mar 1;5(3):351-357. doi: 10.1001/jamaoncol.2018.5428.

11.

DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death.

Thibault B, Genre L, Le Naour A, Broca C, Mery E, Vuagniaux G, Delord JP, Wiedemann N, Couderc B.

Sci Rep. 2018 Dec 14;8(1):17862. doi: 10.1038/s41598-018-35860-z.

12.

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.

Leary A, Le Tourneau C, Varga A, Sablin MP, Gomez-Roca C, Guilbaud N, Petain A, Pavlyuk M, Delord JP.

Invest New Drugs. 2019 Aug;37(4):693-701. doi: 10.1007/s10637-018-0688-4. Epub 2018 Dec 14.

13.

First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.

Elez E, Gomez-Roca C, Soto Matos-Pita A, Argiles G, Valentin T, Coronado C, Iglesias J, Macarulla T, Betrian S, Fudio S, Zaragoza K, Tabernero J, Delord JP.

Invest New Drugs. 2019 Aug;37(4):674-683. doi: 10.1007/s10637-018-0674-x. Epub 2018 Nov 9.

PMID:
30411218
14.

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J.

JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628.

PMID:
30383184
15.

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.

Martin N, Isambert N, Gomez-Roca C, Goeldner RG, Zanetta S, Sadrolhefazi B, de Mont-Serrat H, Campone M, Delord JP.

Cancer Chemother Pharmacol. 2018 Dec;82(6):979-986. doi: 10.1007/s00280-018-3689-2. Epub 2018 Oct 22.

16.

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.

Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P.

JAMA Oncol. 2019 Jan 1;5(1):74-82. doi: 10.1001/jamaoncol.2018.4224.

17.

Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology.

Cabarrou B, Sfumato P, Mourey L, Leconte E, Balardy L, Martinez A, Delord JP, Boher JM, Brain E, Filleron T.

Eur J Cancer. 2018 Nov;103:120-126. doi: 10.1016/j.ejca.2018.07.136. Epub 2018 Sep 14.

PMID:
30223225
18.

A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.

Rodon J, Curigliano G, Delord JP, Harb W, Azaro A, Han Y, Wilke C, Donnet V, Sellami D, Beck T.

Oncotarget. 2018 Aug 3;9(60):31709-31718. doi: 10.18632/oncotarget.25854. eCollection 2018 Aug 3.

19.

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.

Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, Wallmark JM, Keam B, Delord JP, Aggarwal R, Gould M, Yang P, Keefe SM, Piha-Paul SA.

Ann Oncol. 2018 Aug 1;29(8):1807-1813. doi: 10.1093/annonc/mdy232.

PMID:
29992241
20.

Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.

Le Naour A, Mevel R, Thibault B, Courtais E, Chantalat E, Delord JP, Couderc B, Guillermet-Guibert J, Martinez A.

Oncotarget. 2018 Jun 5;9(43):27220-27232. doi: 10.18632/oncotarget.25513. eCollection 2018 Jun 5.

21.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF.

Cancer Discov. 2018 Jul;8(7):812-821. doi: 10.1158/2159-8290.CD-18-0229. Epub 2018 May 30.

22.

Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.

Hiret S, Isambert N, Gomez-Roca C, Bennouna J, Sassi M, de Mont-Serrat H, Fan J, Schnell D, Delord JP.

Invest New Drugs. 2018 Dec;36(6):1044-1059. doi: 10.1007/s10637-018-0601-1. Epub 2018 May 29.

PMID:
29808308
23.

[WHO classification of head and neck tumours 2017: Main novelties and update of diagnostic methods].

Sarradin V, Siegfried A, Uro-Coste E, Delord JP.

Bull Cancer. 2018 Jun;105(6):596-602. doi: 10.1016/j.bulcan.2018.04.004. Review. French.

PMID:
29759330
24.

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C.

J Clin Oncol. 2018 Oct 20;36(30):3007-3014. doi: 10.1200/JCO.2018.78.2292. Epub 2018 May 7.

PMID:
29733771
25.

The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients.

Longué M, Cabarrou B, Wallet J, Brodowicz T, Roché H, Boher JM, Delord JP, Penel N, Filleron T.

Ann Oncol. 2018 Jul 1;29(7):1588-1593. doi: 10.1093/annonc/mdy168.

PMID:
29722789
26.

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.

Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Tourneau CL, van Brummelen EMJ, Varga A, Salgado R, Loi S, Saraf S, Pietrangelo D, Karantza V, Tan AR.

Clin Cancer Res. 2018 Jun 15;24(12):2804-2811. doi: 10.1158/1078-0432.CCR-17-3452. Epub 2018 Mar 20.

27.

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.

Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B.

Am J Clin Oncol. 2018 Feb 21. doi: 10.1097/COC.0000000000000429. [Epub ahead of print]

28.

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

Bahleda R, Varga A, Bergé Y, Soria JC, Schnell D, Tschoepe I, Uttenreuther-Fischer M, Delord JP.

Br J Cancer. 2018 Feb 6;118(3):344-352. doi: 10.1038/bjc.2017.436. Epub 2018 Jan 16.

29.

Fluorescence-guided surgery for cancer patients: a proof of concept study on human xenografts in mice and spontaneous tumors in pets.

Mery E, Golzio M, Guillermet S, Lanore D, Le Naour A, Thibault B, Tilkin-Mariamé AF, Bellard E, Delord JP, Querleu D, Ferron G, Couderc B.

Oncotarget. 2017 Nov 30;8(65):109559-109574. doi: 10.18632/oncotarget.22728. eCollection 2017 Dec 12.

30.

Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.

Massabeau C, Khalifa J, Filleron T, Modesto A, Bigay-Gamé L, Plat G, Dierickx L, Aziza R, Rouquette I, Gomez-Roca C, Mounier M, Delord JP, Toulas C, Olivier P, Chatelut E, Mazières J, Cohen-Jonathan Moyal E.

Clin Lung Cancer. 2018 May;19(3):e277-e285. doi: 10.1016/j.cllc.2017.11.002. Epub 2017 Nov 21.

PMID:
29221762
31.

Comparison of variable selection methods for high-dimensional survival data with competing events.

Gilhodes J, Zemmour C, Ajana S, Martinez A, Delord JP, Leconte E, Boher JM, Filleron T.

Comput Biol Med. 2017 Dec 1;91:159-167. doi: 10.1016/j.compbiomed.2017.10.021. Epub 2017 Oct 20.

PMID:
29078093
32.

First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.

Schöffski P, Delord JP, Brain E, Robert J, Dumez H, Gasmi J, Trouet A.

Eur J Cancer. 2017 Nov;86:240-247. doi: 10.1016/j.ejca.2017.09.009. Epub 2017 Oct 19.

PMID:
29055839
33.

[Observational study of outpatient unit duration of stay depending on the route of administration (intravenous vs subcutaneous) for a targeted therapy].

Despiau F, Zagala Y, Delord JP, Montastruc M, Lacaze JL, Ferrand R, Bombail M.

Bull Cancer. 2017 Oct;104(10):869-874. doi: 10.1016/j.bulcan.2017.08.007. Epub 2017 Oct 13. French.

PMID:
29032944
34.

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.

Temam S, Spicer J, Farzaneh F, Soria JC, Oppenheim D, McGurk M, Hollebecque A, Sarini J, Hussain K, Soehrman Brossard S, Manenti L, Evers S, Delmar P, Di Scala L, Mancao C, Feuerhake F, Andries L, Ott MG, Passioukov A, Delord JP.

Ann Oncol. 2017 Nov 1;28(11):2827-2835. doi: 10.1093/annonc/mdx489.

35.

Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.

Ravaud A, Gomez-Roca C, Picat MQ, Digue L, Chevreau C, Gimbert A, Chauzit E, Sitta R, Cornelis F, Asselineau J, Aziza R, Daste A, Quemener C, Baud J, Bikfalvi A, Pedenon-Périchout D, Doussau A, Molimard M, Delord JP.

Eur J Cancer. 2017 Nov;85:39-48. doi: 10.1016/j.ejca.2017.07.031. Epub 2017 Sep 5.

PMID:
28886476
36.

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.

Aboudaram A, Modesto A, Chaltiel L, Gomez-Roca C, Boulinguez S, Sibaud V, Delord JP, Chira C, Delannes M, Moyal E, Meyer N.

Melanoma Res. 2017 Oct;27(5):485-491. doi: 10.1097/CMR.0000000000000386.

PMID:
28858075
37.

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.

Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan R, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart DD, Moutouh-de Parseval L, Demuth T, Dummer R.

Clin Cancer Res. 2017 Sep 15;23(18):5339-5348. doi: 10.1158/1078-0432.CCR-16-2923. Epub 2017 Jun 13.

38.

Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors.

Bétrian S, Gomez-Roca C, Vigarios E, Delord JP, Sibaud V.

JAMA Dermatol. 2017 Jul 1;153(7):723-725. doi: 10.1001/jamadermatol.2017.0500. No abstract available.

PMID:
28538953
39.

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM.

Cancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31.

40.

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.

Ravaud A, de la Fouchardière C, Caron P, Doussau A, Do Cao C, Asselineau J, Rodien P, Pouessel D, Nicolli-Sire P, Klein M, Bournaud-Salinas C, Wemeau JL, Gimbert A, Picat MQ, Pedenon D, Digue L, Daste A, Catargi B, Delord JP.

Eur J Cancer. 2017 May;76:110-117. doi: 10.1016/j.ejca.2017.01.029. Epub 2017 Mar 20.

PMID:
28301826
41.

Development of Photoonycholysis with Vandetanib Therapy.

Negulescu M, Zerdoud S, Boulinguez S, Tournier E, Delord JP, Baran R, Sibaud V.

Skin Appendage Disord. 2017 Jan;2(3-4):146-151. doi: 10.1159/000452425. Epub 2016 Nov 3.

42.

Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine.

Husseini F, Delord JP, Fournel-Federico C, Guitton J, Erbs P, Homerin M, Halluard C, Jemming C, Orange C, Limacher JM, Kurtz JE.

Ann Oncol. 2017 Jan 1;28(1):169-174. doi: 10.1093/annonc/mdw440.

PMID:
28177438
43.

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.

Belin L, Kamal M, Mauborgne C, Plancher C, Mulot F, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Ricci F, Alt M, Loirat D, Sablin MP, Paoletti X, Servois V, Le Tourneau C.

Ann Oncol. 2017 Mar 1;28(3):590-596. doi: 10.1093/annonc/mdw666.

PMID:
27993804
44.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.

Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM Jr, Blumenschein G Jr.

J Thorac Oncol. 2017 Mar;12(3):556-566. doi: 10.1016/j.jtho.2016.11.2218. Epub 2016 Nov 19.

45.

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J.

J Clin Oncol. 2017 Jan 10;35(2):157-165. Epub 2016 Nov 21. Erratum in: J Clin Oncol. 2017 Mar 10;35(8):926. J Clin Oncol. 2019 Feb 1;37(4):358.

PMID:
27870574
46.

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.

Betrian S, Ysebaert L, Heider KH, Delord JP, Fournié JJ, Quillet-Mary A.

Blood Cancer J. 2016 Nov 11;6(11):e496. doi: 10.1038/bcj.2016.106. No abstract available.

47.

[Subgroup analysis and forest plots: Limitations and interests].

Filleron T, Gilhodes J, Delord JP, Cabarrou B.

Bull Cancer. 2017 Jan;104(1):92-100. doi: 10.1016/j.bulcan.2016.09.023. Epub 2016 Nov 4. Review. French.

PMID:
27823809
48.

[The role of the bed manager nurse in medical oncology].

Despiau F, Bombail M, Marion J, Delord JP.

Soins. 2016 Oct;61(809):18-21. doi: 10.1016/j.soin.2016.08.002. French.

49.

How to report toxicity associated with targeted therapies?

Cabarrou B, Boher JM, Bogart E, Tresch-Bruneel E, Penel N, Ravaud A, Escudier B, Mahier Ait-Oukhatar C, Delord JP, Roché H, Filleron T.

Ann Oncol. 2016 Aug;27(8):1633-8. doi: 10.1093/annonc/mdw218. Epub 2016 May 23.

PMID:
27217543
50.

Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.

Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP.

Curr Opin Oncol. 2016 Jul;28(4):254-63. doi: 10.1097/CCO.0000000000000290. Review.

PMID:
27136138

Supplemental Content

Loading ...
Support Center